Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use
We evaluated ovarian follicular development in women during compliant use of oral contraceptives (OC). Thirty-six healthy women received: [35 μg ethinyl estradiol (21)/180 μg norgestimate (7), 215 μg norgestimate (7), 250 μg norgestimate (7)]; [30 μg ethinyl estradiol (21)/150 μg desogestrel (21)];...
Gespeichert in:
| Veröffentlicht in: | Contraception (Stoneham) 2004-11, Vol.70 (5), p.371-377 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 377 |
|---|---|
| container_issue | 5 |
| container_start_page | 371 |
| container_title | Contraception (Stoneham) |
| container_volume | 70 |
| creator | Baerwald, A.R. Olatunbosun, O.A. Pierson, R.A. |
| description | We evaluated ovarian follicular development in women during compliant use of oral contraceptives (OC). Thirty-six healthy women received: [35 μg ethinyl estradiol (21)/180 μg norgestimate (7), 215 μg norgestimate (7), 250 μg norgestimate (7)]; [30 μg ethinyl estradiol (21)/150 μg desogestrel (21)]; or [20 μg ethinyl estradiol (21)/100 μg levonorgestrel (21)] for 3 consecutive 28-day cycles. Transvaginal ultrasonography was performed every third day to monitor follicular development. If a follicle reached ≥14 mm, ultrasonography was performed daily and blood drawn every other day to determine estradiol-17β concentrations. Seventeen of 36 women (47%) grew follicles ≥10 mm. Nine of the 17 women (53%) grew follicles ≥14 mm, in association with increased serum concentrations of estradiol-17β. Thirty-seven of 43 follicles ≥10 mm (86%) emerged during the hormone-free interval (HFI). No ovulations were observed. Our results supported the hypothesis that follicular development to an ostensibly ovulatory diameter occurs during compliant OC use, in association with loss of endocrine suppression during the HFI. |
| doi_str_mv | 10.1016/j.contraception.2004.05.006 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67009504</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0010782404001556</els_id><sourcerecordid>67009504</sourcerecordid><originalsourceid>FETCH-LOGICAL-c404t-31bafef8abb7f774ffaddb106a2b3e380d083045e5af3bb36c970ff270a1f433</originalsourceid><addsrcrecordid>eNqNkE9r3DAUxEVISDabfoUiKORm92llWV56CiF_CoFcchey9NRosaWtJBv67etlF9LecprLzJs3P0K-MagZsPb7rjYxlKQN7ouPod4ANDWIGqA9IyvWyW0FgnXnZAXAoJLdprki1znvAEBuhbwkV0wIaLgUK-JeZ528DtTFYfBmGnSiFmcc4n7EUKjP1AdfvC5oqZ2SD79oeUf6HtMYA1YuIS6OgmnWA42OxrToPw_OSKeMN-TC6SHjl5Ouydvjw9v9c_Xy-vTz_u6lMg00peKs1w5dp_teOikb57S1PYNWb3qOvAMLHYdGoNCO9z1vzVaCcxsJmrmG8zW5PZ7dp_h7wlzU6LPBYdAB45RVKwG2h-lr8uNoNCnmnNCpffKjTn8UA3WgrHbqP8rqQFmBUAvlJf31VDP1I9qP7AnrYng4GnDZOntMKhuPwaD1CU1RNvpPFf0F9-2ZcA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67009504</pqid></control><display><type>article</type><title>Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Baerwald, A.R. ; Olatunbosun, O.A. ; Pierson, R.A.</creator><creatorcontrib>Baerwald, A.R. ; Olatunbosun, O.A. ; Pierson, R.A.</creatorcontrib><description>We evaluated ovarian follicular development in women during compliant use of oral contraceptives (OC). Thirty-six healthy women received: [35 μg ethinyl estradiol (21)/180 μg norgestimate (7), 215 μg norgestimate (7), 250 μg norgestimate (7)]; [30 μg ethinyl estradiol (21)/150 μg desogestrel (21)]; or [20 μg ethinyl estradiol (21)/100 μg levonorgestrel (21)] for 3 consecutive 28-day cycles. Transvaginal ultrasonography was performed every third day to monitor follicular development. If a follicle reached ≥14 mm, ultrasonography was performed daily and blood drawn every other day to determine estradiol-17β concentrations. Seventeen of 36 women (47%) grew follicles ≥10 mm. Nine of the 17 women (53%) grew follicles ≥14 mm, in association with increased serum concentrations of estradiol-17β. Thirty-seven of 43 follicles ≥10 mm (86%) emerged during the hormone-free interval (HFI). No ovulations were observed. Our results supported the hypothesis that follicular development to an ostensibly ovulatory diameter occurs during compliant OC use, in association with loss of endocrine suppression during the HFI.</description><identifier>ISSN: 0010-7824</identifier><identifier>EISSN: 1879-0518</identifier><identifier>DOI: 10.1016/j.contraception.2004.05.006</identifier><identifier>PMID: 15504375</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject><![CDATA[Adolescent ; Adult ; Contraception ; Contraceptives, Oral, Combined - administration & dosage ; Contraceptives, Oral, Combined - pharmacology ; Desogestrel - administration & dosage ; Desogestrel - pharmacology ; Drug Administration Schedule ; Endometrium - diagnostic imaging ; Endometrium - drug effects ; Ethinyl Estradiol - administration & dosage ; Ethinyl Estradiol - pharmacology ; Female ; Follicle ; Hormone-free interval ; Humans ; Levonorgestrel - administration & dosage ; Levonorgestrel - pharmacology ; Norgestrel - administration & dosage ; Norgestrel - analogs & derivatives ; Norgestrel - pharmacology ; Oral ; Ovarian Follicle - diagnostic imaging ; Ovarian Follicle - drug effects ; Treatment Outcome ; Ultrasonography]]></subject><ispartof>Contraception (Stoneham), 2004-11, Vol.70 (5), p.371-377</ispartof><rights>2004 Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c404t-31bafef8abb7f774ffaddb106a2b3e380d083045e5af3bb36c970ff270a1f433</citedby><cites>FETCH-LOGICAL-c404t-31bafef8abb7f774ffaddb106a2b3e380d083045e5af3bb36c970ff270a1f433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.contraception.2004.05.006$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>315,782,786,3554,27933,27934,46004</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15504375$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Baerwald, A.R.</creatorcontrib><creatorcontrib>Olatunbosun, O.A.</creatorcontrib><creatorcontrib>Pierson, R.A.</creatorcontrib><title>Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use</title><title>Contraception (Stoneham)</title><addtitle>Contraception</addtitle><description>We evaluated ovarian follicular development in women during compliant use of oral contraceptives (OC). Thirty-six healthy women received: [35 μg ethinyl estradiol (21)/180 μg norgestimate (7), 215 μg norgestimate (7), 250 μg norgestimate (7)]; [30 μg ethinyl estradiol (21)/150 μg desogestrel (21)]; or [20 μg ethinyl estradiol (21)/100 μg levonorgestrel (21)] for 3 consecutive 28-day cycles. Transvaginal ultrasonography was performed every third day to monitor follicular development. If a follicle reached ≥14 mm, ultrasonography was performed daily and blood drawn every other day to determine estradiol-17β concentrations. Seventeen of 36 women (47%) grew follicles ≥10 mm. Nine of the 17 women (53%) grew follicles ≥14 mm, in association with increased serum concentrations of estradiol-17β. Thirty-seven of 43 follicles ≥10 mm (86%) emerged during the hormone-free interval (HFI). No ovulations were observed. Our results supported the hypothesis that follicular development to an ostensibly ovulatory diameter occurs during compliant OC use, in association with loss of endocrine suppression during the HFI.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Contraception</subject><subject>Contraceptives, Oral, Combined - administration & dosage</subject><subject>Contraceptives, Oral, Combined - pharmacology</subject><subject>Desogestrel - administration & dosage</subject><subject>Desogestrel - pharmacology</subject><subject>Drug Administration Schedule</subject><subject>Endometrium - diagnostic imaging</subject><subject>Endometrium - drug effects</subject><subject>Ethinyl Estradiol - administration & dosage</subject><subject>Ethinyl Estradiol - pharmacology</subject><subject>Female</subject><subject>Follicle</subject><subject>Hormone-free interval</subject><subject>Humans</subject><subject>Levonorgestrel - administration & dosage</subject><subject>Levonorgestrel - pharmacology</subject><subject>Norgestrel - administration & dosage</subject><subject>Norgestrel - analogs & derivatives</subject><subject>Norgestrel - pharmacology</subject><subject>Oral</subject><subject>Ovarian Follicle - diagnostic imaging</subject><subject>Ovarian Follicle - drug effects</subject><subject>Treatment Outcome</subject><subject>Ultrasonography</subject><issn>0010-7824</issn><issn>1879-0518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkE9r3DAUxEVISDabfoUiKORm92llWV56CiF_CoFcchey9NRosaWtJBv67etlF9LecprLzJs3P0K-MagZsPb7rjYxlKQN7ouPod4ANDWIGqA9IyvWyW0FgnXnZAXAoJLdprki1znvAEBuhbwkV0wIaLgUK-JeZ528DtTFYfBmGnSiFmcc4n7EUKjP1AdfvC5oqZ2SD79oeUf6HtMYA1YuIS6OgmnWA42OxrToPw_OSKeMN-TC6SHjl5Ouydvjw9v9c_Xy-vTz_u6lMg00peKs1w5dp_teOikb57S1PYNWb3qOvAMLHYdGoNCO9z1vzVaCcxsJmrmG8zW5PZ7dp_h7wlzU6LPBYdAB45RVKwG2h-lr8uNoNCnmnNCpffKjTn8UA3WgrHbqP8rqQFmBUAvlJf31VDP1I9qP7AnrYng4GnDZOntMKhuPwaD1CU1RNvpPFf0F9-2ZcA</recordid><startdate>20041101</startdate><enddate>20041101</enddate><creator>Baerwald, A.R.</creator><creator>Olatunbosun, O.A.</creator><creator>Pierson, R.A.</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20041101</creationdate><title>Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use</title><author>Baerwald, A.R. ; Olatunbosun, O.A. ; Pierson, R.A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c404t-31bafef8abb7f774ffaddb106a2b3e380d083045e5af3bb36c970ff270a1f433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Contraception</topic><topic>Contraceptives, Oral, Combined - administration & dosage</topic><topic>Contraceptives, Oral, Combined - pharmacology</topic><topic>Desogestrel - administration & dosage</topic><topic>Desogestrel - pharmacology</topic><topic>Drug Administration Schedule</topic><topic>Endometrium - diagnostic imaging</topic><topic>Endometrium - drug effects</topic><topic>Ethinyl Estradiol - administration & dosage</topic><topic>Ethinyl Estradiol - pharmacology</topic><topic>Female</topic><topic>Follicle</topic><topic>Hormone-free interval</topic><topic>Humans</topic><topic>Levonorgestrel - administration & dosage</topic><topic>Levonorgestrel - pharmacology</topic><topic>Norgestrel - administration & dosage</topic><topic>Norgestrel - analogs & derivatives</topic><topic>Norgestrel - pharmacology</topic><topic>Oral</topic><topic>Ovarian Follicle - diagnostic imaging</topic><topic>Ovarian Follicle - drug effects</topic><topic>Treatment Outcome</topic><topic>Ultrasonography</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Baerwald, A.R.</creatorcontrib><creatorcontrib>Olatunbosun, O.A.</creatorcontrib><creatorcontrib>Pierson, R.A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Contraception (Stoneham)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Baerwald, A.R.</au><au>Olatunbosun, O.A.</au><au>Pierson, R.A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use</atitle><jtitle>Contraception (Stoneham)</jtitle><addtitle>Contraception</addtitle><date>2004-11-01</date><risdate>2004</risdate><volume>70</volume><issue>5</issue><spage>371</spage><epage>377</epage><pages>371-377</pages><issn>0010-7824</issn><eissn>1879-0518</eissn><abstract>We evaluated ovarian follicular development in women during compliant use of oral contraceptives (OC). Thirty-six healthy women received: [35 μg ethinyl estradiol (21)/180 μg norgestimate (7), 215 μg norgestimate (7), 250 μg norgestimate (7)]; [30 μg ethinyl estradiol (21)/150 μg desogestrel (21)]; or [20 μg ethinyl estradiol (21)/100 μg levonorgestrel (21)] for 3 consecutive 28-day cycles. Transvaginal ultrasonography was performed every third day to monitor follicular development. If a follicle reached ≥14 mm, ultrasonography was performed daily and blood drawn every other day to determine estradiol-17β concentrations. Seventeen of 36 women (47%) grew follicles ≥10 mm. Nine of the 17 women (53%) grew follicles ≥14 mm, in association with increased serum concentrations of estradiol-17β. Thirty-seven of 43 follicles ≥10 mm (86%) emerged during the hormone-free interval (HFI). No ovulations were observed. Our results supported the hypothesis that follicular development to an ostensibly ovulatory diameter occurs during compliant OC use, in association with loss of endocrine suppression during the HFI.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>15504375</pmid><doi>10.1016/j.contraception.2004.05.006</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0010-7824 |
| ispartof | Contraception (Stoneham), 2004-11, Vol.70 (5), p.371-377 |
| issn | 0010-7824 1879-0518 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67009504 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adolescent Adult Contraception Contraceptives, Oral, Combined - administration & dosage Contraceptives, Oral, Combined - pharmacology Desogestrel - administration & dosage Desogestrel - pharmacology Drug Administration Schedule Endometrium - diagnostic imaging Endometrium - drug effects Ethinyl Estradiol - administration & dosage Ethinyl Estradiol - pharmacology Female Follicle Hormone-free interval Humans Levonorgestrel - administration & dosage Levonorgestrel - pharmacology Norgestrel - administration & dosage Norgestrel - analogs & derivatives Norgestrel - pharmacology Oral Ovarian Follicle - diagnostic imaging Ovarian Follicle - drug effects Treatment Outcome Ultrasonography |
| title | Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-11-29T23%3A51%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Ovarian%20follicular%20development%20is%20initiated%20during%20the%20hormone-free%20interval%20of%20oral%20contraceptive%20use&rft.jtitle=Contraception%20(Stoneham)&rft.au=Baerwald,%20A.R.&rft.date=2004-11-01&rft.volume=70&rft.issue=5&rft.spage=371&rft.epage=377&rft.pages=371-377&rft.issn=0010-7824&rft.eissn=1879-0518&rft_id=info:doi/10.1016/j.contraception.2004.05.006&rft_dat=%3Cproquest_cross%3E67009504%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=67009504&rft_id=info:pmid/15504375&rft_els_id=S0010782404001556&rfr_iscdi=true |